DiscGenics
Blood & Organ Banks · Utah, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5940 W Harold Gatty Dr, Salt Lake City, ...Phone Number
(801) 410-0703Website
www.discgenics.comRevenue
$6.2 MillionIndustry
ZI Rank: 4
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
5
3
4
3
4
About DiscGenics
DiscGenics is dedicated to developing innovative regenerative therapies aimed at alleviating pain and restoring function for patients suffering from degenerative diseases of the spine. Their primary product candidate, IDCT, is an allogeneic, injectable cell therapy designed to treat mild to moderate lumbar disc degeneration. The company focuses on engineering specialized therapeutic progenitor cells, known as Discogenic Cells, to address the complexities of degenerated discs. DiscGenics aims to revolutionize the treatment of chronic back pain for millions of patients.Explore more
DiscGenics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is DiscGenics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if DiscGenics had a recent Job posting/layoffs
Check out if DiscGenics is spiking on competitors!
Funding: Get notified immidiatlly once DiscGenics has new funding data
Product Launch: Get notified when DiscGenics launches new products
Check if DiscGenics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at DiscGenics
Website visits: Recent activity has been detected on your website
DiscGenics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on DiscGenics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at DiscGenics
Find 2 more new buyers
Compare Similar Companies to DiscGenics
Compare insights from companies similar to DiscGenics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
DiscGenics is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
DiscGenics is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about DiscGenics.
DiscGenics financials insights
Gather financial insights about DiscGenics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series A
$7M
2017
Series B
$14M
2020
Debt
$350K
Series C
$50M
2021
Debt
$562K
DiscGenics Tech Stack
A closer look at the technologies used by DiscGenics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
, according to a front-line source in product development, is in the midst of initiatives related to quality assurance. The organization is currently evaluating ETQ Reliance.
Quality Assurance, Product Development, Product Management
Award
Award
Project
A mid-level source in Facilities Management has indicated that the organization is in the midst of initiatives related to enterprise resource planning (ERP) software. The organization is rolling out integrated modules through NetSuite to support these efforts.
Business Development, Enterprise Software, Operating Systems, Software, Facilities Management
Project
Business Intelligence, Analytics & Insights, Facilities Management
DiscGenics News & Media
DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease
Receives FDA acceptance on Phase III clinical protocols for parallel pivotal and confirmatory trials Achieves alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of Phase III program SALT LAKE CITY, July 16, 2024 /PRNewswire/ -- DiscGenics, Inc., a privately held,...DiscGenics Announces the International Journal of Spine Surgery Has Published Results from an FDA-Approved Study of an Allogeneic Disc Progenitor Cell Therapy for the Treatment of Adults with Lumbar Disc Degeneration
SALT LAKE CITY, July 9, 2024 /PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies for musculoskeletal degeneration, today announced publication of results in the International Journal...DiscGenics to Present at Canaccord Genuity 2024 Musculoskeletal Conference
SALT LAKE CITY, Feb. 8, 2024 /PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies for musculoskeletal degeneration, today announced that Flagg Flanagan, Chief Executive Officer and...DiscGenics to Present at Biotech Showcase 2024
SALT LAKE CITY, Jan. 4, 2024 /PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies for musculoskeletal degeneration, today announced that Flagg Flanagan, Chief Executive Officer and...
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding DiscGenics
Sign Up For FreeTo access detailed company insights
DiscGenics is dedicated to developing innovative regenerative therapies aimed at alleviating pain and restoring function for patients suffering from degenerative diseases of the spine. Their primary product candidate, IDCT, is an allogeneic, injectable cell therapy designed to treat mild to moderate lumbar disc degeneration. The company focuses on... Read More
